Baird Downgrades Karyopharm Therapeutics (KPTI) to Neutral

July 31, 2026 3:15 AM

Baird analyst Colleen Kusy downgraded Karyopharm Therapeutics (NASDAQ: KPTI) from Outperform to Neutral with a price target of $3.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found